var docs;if (!docs) docs =[]; docs["112"]={"11202":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Xipamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Xipamide may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for hypokalemia and QTc prolongation if xipamide is combined with QTc-prolonging agents.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The xipamide summary of product characteristics states that xipamide-induced hypokalemia combined with agents known to prolong the QTc interval may increase the risk for QTc-prolongation and torsades de pointe.<sup>1</sup> Patients should be monitored closely for hypokalemia and QTc-prolongation if these agents are combined.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Diurexan (xipamide) [summary of product characteristics]. Bishop's Stortford, UK: Meda Pharmaceuticals Ltd; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11203":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Xipamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Xipamide may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for hypokalemia and QTc prolongation if xipamide is combined with QTc-prolonging agents.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> The xipamide summary of product characteristics states that xipamide-induced hypokalemia combined with agents known to prolong the QTc interval may increase the risk for QTc-prolongation and torsades de pointe.<sup>1</sup> Patients should be monitored closely for hypokalemia and QTc-prolongation if these agents are combined.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Diurexan (xipamide) [summary of product characteristics]. Bishop's Stortford, UK: Meda Pharmaceuticals Ltd; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11204":"<p><b>Title</b> Neuromuscular-Blocking Agents / Pholcodine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pholcodine may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor patients with prior pholcodine use for anaphylactic reactions to neuromuscular-blocking agents.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Prior consumption of pholcodine has been associated with an increased risk of developing IgE-mediated anaphylactic reactions to neuromuscular-blocking agents.<sup>1,2,3,4,5,6,7</sup> The United Kingdom product labeling recognizes this potential interaction; however, no specific recommendations regarding use or avoidance of this combination are provided.<sup>8</sup> In 2012, following a formal review of available data, The European Medicines Agency concluded that existing evidence on the potential interaction is weak and that the benefits of pholcodine outweigh its risks.<sup>9</sup> Further, the agency advised that pholcodine use continue unrestricted throughout the European Union. <br><br>Pholcodine and neuromuscular-blocking agents share the major allergenic epitope, quaternary ammonium ion (QAI).<sup>7</sup> The mechanism of action for the proposed interaction is due to presensitization with IgE antibodies cross-reacting with the QAI epitope.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Pater GH, Florvaag E, Johansson SG, et al. Six years without pholcodine; Norwegians are significantly less IgE-sensitized and clinically more tolerant to neuromuscular blocking agents. <i>Allergy</i>. 2017;72(5):813-819. [Pub Med 27859358]</p>\n<p>2. Katelaris CH, Kurosawa M, Moon HB, et al. Pholcodine consumption and immunoglobulin E-sensitization in atopics from Australia, Korea, and Japan. <i>Asia Pac Allergy</i>. 2014;4(2):86-90. [Pub Med 24809013]</p>\n<p>3. Florvaag E, Johansson SG, Irgens A, et al. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. <i>Allergy</i>. 2011;66(7):955-960. [Pub Med 21241314]</p>\n<p>4. Johansson SG, Florvaag E, Oman H, et al. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. <i>Allergy</i>. 2010;65(4):498-502. [Pub Med 19796197]</p>\n<p>5. Harboe T, Johansson SG, Florvaag E, et al. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. <i>Allergy</i>. 2007;62(12):1445-1450. [Pub Med 17983379]</p>\n<p>6. Florvaag E, Johansson SG, Oman H, et al. Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. <i>Allergy</i>. 2006;61(1):49-55. [Pub Med 16364156]</p>\n<p>7. Florvaag E, Johansson SG, Oman H, et al. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. <i>Acta Anaesthesiol Scand</i>. 2005;49(4):437-444. [Pub Med 15777289]</p>\n<p>8. Covonia Dry Cough (pholcodine) solution [summary of product characteristics]. Huddersfield, United Kingdom: Thornton and Ross Ltd; April 2016.</p>\n<p>9. European Medicines Agency. European Medicines Agency confirms positive benefit-risk balance of pholcodine-containing cough medicines [Internet]. London: European Medicines Agency; c19952014 [cited 2017 April13]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Pholcodine/human_referral_000286.jsp&amp;mid=WC0b01ac05805c516f</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11205":"<p><b>Title</b> Deutetrabenazine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Deutetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The total daily dose of deutetrabenazine should not exceed 36 mg, and the maximum single dose of deutetrabenazine should not exceed 18 mg with concurrent use of a strong CYP2D6 inhibitor. Monitor patient response closely as the risk for adverse effects may be increased with use of this combination.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The average AUC of active deuterated dihydro metabolites of deutetrabenazine (alpha-HTBZ and beta-HTBZ) were increased by 1.9- and 6.5-fold when administered following the strong CYP2D6 inhibitor paroxetine (20 mg/day for 8 days).<sup>1</sup> The average half-life of the active metabolites was also 1.5- to 2.7-fold longer following administration of the strong CYP2D6 inhibitor.<br><br>The clinical significance of this apparent interaction is uncertain, but the deutetrabenazine labeling recommends limiting both the maximum daily dose and maximum single dose when used together with a strong CYP2D6 inhibitor.<sup>1</sup><br><br>The likely mechanism for this interaction is impaired CYP2D6 metabolism of the active alpha-HTBZ and beta-HTBZ metabolites.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11206":"<p><b>Title</b> Deutetrabenazine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of a monoamine oxidase (MAO) inhibitor together with deutetrabenazine is contraindicated. Similarly, use of deutetrabenazine within 14 days of the discontinuation of an MAO inhibitor is also contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The deutetrabenazine labeling lists concurrent use with an MAO inhibitor or within 14 days of discontinuing an MAO inhibitor as contraindicated.<sup>1</sup> The specific mechanism for this interaction is not described in the labeling, but since deutetrabenazine acts to deplete nerve terminal monoamine neurotransmitters and synaptic uptake of monoamine neurotransmitters, MAO inhibitors could interfere with deutetrabenazine effectiveness by interfering with monoamine metabolism. Whether impaired vesicle uptake together with reduced MAO-mediated breakdown could result in a risk for toxicity due to excessive neurotransmitter availability or activity is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11207":"<p><b>Title</b> Deutetrabenazine / Reserpine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Reserpine may enhance the adverse/toxic effect of Deutetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of deutetrabenazine is contraindicated in patients taking reserpine. At least 20 days should pass between stopping reserpine and administration of deutetrabenazine. The labeling recommends that, following discontinuation of reserpine, clinicians wait for chorea to reemerge before starting deutetrabenazine.</p> \n<p><b>Discussion</b> The active deuterated dihydro metabolites of deutetrabenazine act as inhibitors of VMAT2 and work to deplete monoamine neurotransmitter stores in nerve terminals. Since reserpine also binds to VMAT2 and has actions that last for several days, the deutetrabenazine labeling contraindicates concurrent use with reserpine and recommends not initiating deutetrabenazine until at least 20 days following discontinuation of reserpine.<sup>1</sup><br><br>The concern with concurrent use is excessive depletion of CNS serotonin or norepinephrine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11208":"<p><b>Title</b> Tetrabenazine / Deutetrabenazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Deutetrabenazine may enhance the adverse/toxic effect of Tetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of deutetrabenazine together with tetrabenazine is contraindicated. Deutetrabenazine can be initiated the day after discontinuation of tetrabenazine, and the deutetrabenazine labeling contains details of how to initiate deutetrabenazine following the discontinuation of tetrabenazine.</p> \n<p><b>Discussion</b> Concurrent use of deutetrabenazine together with tetrabenazine is contraindicated. Details regarding how to initiate deutetrabenazine following the discontinuation of tetrabenazine are provided in the prescribing information.<sup>1</sup><br><br>The likely concern with concurrent use is an excessive or overlapping effect on neuronal monoamine neurotransmitter stores.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11209":"<p><b>Title</b> Antipsychotic Agents / Deutetrabenazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Deutetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of movement disorders such as parkinsonism or akathisia, as well as for neuroleptic malignant syndrome with concurrent use of deutetrabenazine and drugs with dopamine antagonist activities, such as antipsychotic agents.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The active deuterated dihydro metabolites of deutetrabenazine act as inhibitors of VMAT2 and work to deplete monoamine neurotransmitter stores in nerve terminals. According to deutetrabenazine labeling, akathisia, agitation, or restlessness was reported in 4% of deutetrabenazine users as compared to 2% in placebo-treated patients.<sup>1</sup> The labeling also contains warnings about parkinsonism and neuroleptic malignant syndrome, but it is unclear if such events have been reported with deutetrabenazine, though they have been associated with the closely related drug tetrabenazine.<br><br>Because many drugs with central dopamine antagonist actions have also been associated with movement disorders and neuroleptic malignant syndrome, the deutetrabenazine labeling states that use of such a combination may increase the risk for such effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11210":"<p><b>Title</b> Metoclopramide / Deutetrabenazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Deutetrabenazine may enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of movement disorders such as parkinsonism or akathisia, as well as for neuroleptic malignant syndrome with concurrent use of deutetrabenazine and drugs with dopamine antagonist activities, such as metoclopramide.</p> \n<p><b>Discussion</b> The active deuterated dihydro metabolites of deutetrabenazine act as inhibitors of VMAT2 and work to deplete monoamine neurotransmitter stores in nerve terminals. According to deutetrabenazine labeling, akathisia, agitation, or restlessness was reported in 4% of deutetrabenazine users as compared to 2% in placebo-treated patients.<sup>1</sup> The labeling also contains warnings about parkinsonism and neuroleptic malignant syndrome, but it is unclear if such events have been reported with deutetrabenazine, though they have been associated with the closely related drug tetrabenazine.<br><br>Because many drugs with central dopamine antagonist actions have also been associated with movement disorders and neuroleptic malignant syndrome, the deutetrabenazine labeling states that use of such a combination may increase the risk for such effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11211":"<p><b>Title</b> Valbenazine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of valbenazine and strong CYP3A4 inducers is not recommended.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the valbenazine prescribing information, the strong CYP3A4 inducer rifampin decreased the valbenazine AUC and maximum serum concentration (Cmax) approximately 70% and 25%, respectively.<sup>1</sup> The AUC and Cmax of the valbenazine active metabolite decreased approximately 80% and 50%, respectively.<sup>1</sup><br><br>Valbenazine prescribing information states that because reduced exposure of valbenazine and its active metabolite may reduce the efficacy of valbenazine, use with strong CYP3A4 inducers is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is due to rifampin-mediated induction of CYP3A4, an enzyme responsible for valbenazine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11212":"<p><b>Title</b> Valbenazine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the valbenazine prescribing information, the strong CYP3A4 inhibitor ketoconazole increased the valbenazine AUC and maximum serum concentration (Cmax) approximately 2.2-fold and 1.5-fold, respectively.<sup>1</sup> The AUC and Cmax of the valbenazine active metabolite increased approximately 2.1-fold and 1.8-fold, respectively.<sup>1</sup><br><br>Valbenazine prescribing information states that because increased exposure of valbenazine and its active metabolite may increase the risk of adverse effects, the dose of valbenazine should be reduced to 40 mg daily when combined with strong CYP3A4 inhibitors.<sup>1</sup><br><br>The mechanism of this interaction is due to ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for valbenazine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11213":"<p><b>Title</b> Valbenazine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased valbenazine effects/toxicities (eg, QT prolongation, somnolence, restlessness, arthralgia, vomiting) if combined with a strong CYP2D6 inhibitor. A dose reduction of valbenazine should be considered if intolerance occurs with this combination.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Valbenazine prescribing information states that the use of valbenazine with a strong CYP2D6 inhibitor is expected to increase the maximum serum concentration and AUC of the valbenazine active metabolite.<sup>1</sup> This increase in metabolite exposure may result in an increased risk for adverse events including QT prolongation, somnolence, restlessness, arthralgia, and vomiting.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11214":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Valbenazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Valbenazine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of valbenazine and monoamine oxidase inhibitors.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Valbenazine prescribing information states that coadministration of valbenazine with monoamine oxidase inhibitors may increase levels of monoamine neurotransmitters in synapses leading to an increased risk of toxicity or adverse reactions, including serotonin syndrome.<sup>1</sup> Given the risk of life-threatening adverse reactions occurring, coadministration of valbenazine and monoamine oxidase inhibitors should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11215":"<p><b>Title</b> Digoxin / Valbenazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valbenazine may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased digoxin serum concentrations and effects if combined with valbenazine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the valbenazine prescribing information, valbenazine increased the digoxin AUC and maximum serum concentration approximately 1.5-fold and 2-fold, respectively.<sup>1</sup><br><br>Valbenazine prescribing information states that digoxin concentrations should be monitored when these drugs are combined and dosage adjustment of digoxin may be necessary to maintain therapeutic concentrations and avoid toxicities.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but valbenazine may inhibit P-glycoprotein, a transporter responsible for digoxin disposition</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11216":"<p><b>Title</b> Valbenazine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Valbenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of valbenazine and St John's wort is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the valbenazine prescribing information, the strong CYP3A4 inducer rifampin decreased the valbenazine AUC and maximum serum concentration (Cmax) approximately 70% and 25%, respectively.<sup>1</sup> The AUC and Cmax of the valbenazine active metabolite decreased approximately 80% and 50%, respectively.<sup>1</sup><br><br>Valbenazine prescribing information states that because reduced exposure of valbenazine and its active metabolite may reduce the efficacy of valbenazine, use with strong CYP3A4 inducers is not recommended.<sup>1</sup> Although St John's wort is most often considered a moderate CYP3A4 inducer, valbenazine prescribing information recommends avoiding concomitant use of valbenazine and St John's wort.<sup>1</sup><br><br>The mechanism of this interaction is due to rifampin-mediated induction of CYP3A4, an enzyme responsible for valbenazine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11217":"<p><b>Title</b> Dextromethorphan / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Dextromethorphan. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider avoiding dextromethorphan in patients taking tipranavir. If combined, monitor closely for increased dextromethorphan effects/toxicities.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 23 healthy volunteers, single dose tipranavir/ritonavir (500 mg/200 mg) increased the dextromethorphan (30 mg single dose) AUC and maximum serum concentration (Cmax) 188% and 164%, respectively.<sup>1</sup> After steady state dosing of tipranavir/ritonavir (500 mg/200 mg twice daily x 5 days) the dextromethorphan AUC and Cmax increased 490% and 363%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to tipranavir-mediated inhibition of CYP2D6, the enzyme primarily responsible for dextromethorphan metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. <i>Clin Pharmacol Ther</i>. 2010;87(6):735-742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20147896\">[PubMed 20147896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11218":"<p><b>Title</b> Pholcodine / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for hypotension when pholcodine is used in combination with blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The pholcodine product labeling states that antihypertensive agents may enhance the blood pressure lowering effect of pholcodine.<sup>1</sup> Specific data regarding this potential interaction are not available; however, pholcodine is structurally similar to morphine and histamine release may play a role.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Covonia Dry Cough (pholcodine) solution [summary of product characteristics]. Huddersfield, United Kingdom: Thornton and Ross Ltd; April 2016.</p>\n<p>2. Baldo BA, Fisher MM, Pham NH. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. <i>Clin Exp Allergy</i>. 2009;39(3):325-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19187323\">[PubMed 19187323]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11219":"<p><b>Title</b> BuPROPion / Dipyrone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dipyrone may decrease the serum concentration of BuPROPion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced response to bupropion.</p> \n<p><b>Discussion</b> According to dipyrone labeling, concurrent use with bupropion may result in decreased bupropion concentrations.<sup>1</sup> The clinical significance of this reported interaction is unclear.<br><br>The specific mechanism for this interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Novalgina (dipyrone) [Brazil prescribing information]. Sau Paulo, SP, Brazil: Sanofi-Aventis Pharmaceuticals Ltda.; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11220":"<p><b>Title</b> Inhalational Anesthetics / Bambuterol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bambuterol may enhance the arrhythmogenic effect of Inhalational Anesthetics. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving bambuterol for increased sensitivity to arrhythmias during treatment with inhalational anesthetics. Some labels specifically recommend avoiding halothane and using caution with other similar agents, while other labels recommend separating administration of an inhaled anesthetic from bambuterol administration by at least 6 hours when possible. Some other bambuterol labels do not mention this possible interaction.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Some bambuterol product labeling states that there is a possible interaction with inhaled anesthetics, with somewhat different recommendations in different labels.<sup>1,2</sup> At least some labels do not list this interaction.<sup>3</sup> The main concern appears to be an elevated risk of arrhythmia during concomitant treatment with inhalational anesthetics.<sup>1</sup> No specific data are available, although some data support an elevated risk of arrhythmia when inhalational anesthetics are combined with some other sympathomimetic drugs (eg, ephedrine, epinephrine).<sup>4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bambec (bambuterol) [Brazil prescribing information]. Cotia, SP, Brazil: AstraZeneca of Brazil Ltda.; October 2016.</p>\n<p>2. Bambunal (bambuterol) [Korea prescribing information]. Guro-dong, Seoul, South Korea: Dongkoo Bio Pharma; November 2016.</p>\n<p>3. Bambec (bambuterol) [summary of product characteristics]. Luton, United Kingdom: AstraZeneca UK Ltd.; June 2016.</p>\n<p>4. Johnston RR, Eger EI II, Wilson C. A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. <i>Anesth Analg</i>. 1976;55(5):709-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=987729\">[PubMed 987729]</a></p>\n<p>5. Navarro R, Weiskopf RB, Moore MA, et al. Humans anesthetized with sevoflurane or isoflurane have similar arrhythmic response to epinephrine. <i>Anesthesiology</i>. 1994;80(3):545-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7511357\">[PubMed 7511357]</a></p>\n<p>6. Moore MA, Weiskopf RB, Eger EI 2nd, Wilson C, Lu G. Arrhythmogenic doses of epinephrine are similar during desflurane or isoflurane anesthesia in humans. <i>Anesthesiology</i>. 1993;79(5):943-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7694528\">[PubMed 7694528]</a></p>\n<p>7. Hahm TS, Lee JJ, Yang MK, Kim JA. Risk factors for an intraoperative arrhythmia during esophagectomy. <i>Yonsei Med J</i>. 2007;48(3):474-479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17594156\">[PubMed 17594156]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11233":"<p><b>Title</b> Alfacalcidol / Anticonvulsants</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Anticonvulsants may diminish the therapeutic effect of Alfacalcidol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required. Regular monitoring of serum 25-hydroxyvitamin D levels in patients receiving chronic therapy with anticonvulsants should be sufficient for management of this possible interaction.</p>\n<div>\n <p><b>Anticonvulsants Interacting Members</b> AcetaZOLAMIDE, Brivaracetam, CarBAMazepine, Divalproex, Eslicarbazepine, Ethosuximide, Ethotoin, Ezogabine, Felbamate, Fosphenytoin, Gabapentin, Lacosamide, LamoTRIgine, LevETIRAcetam, Methsuximide, OXcarbazepine, PENTobarbital, Perampanel, PHENobarbital, Phenytoin, Pregabalin, Primidone, Stiripentol, Sulthiame, Thiopental, TiaGABine, Topiramate, Valproic Acid and Derivatives, Vigabatrin, Zonisamide</p>\n</div> \n<p><b>Discussion</b> The alfacalcidol product label reports that patients receiving anticonvulsants may require an increased dose of alfacalcidol to produce the desired effect.<sup>1</sup> There are no official recommendations for vitamin D replacement in patients treated with anticonvulsants; therefore, general guidelines for daily vitamin D intake should be followed and serum 25-hydroxyvitamin D levels monitored as needed.<sup>2</sup> <br><br>The data for this potential interaction is primarily with anticonvulsants shown to induce the CYP3A4 enzyme.<sup>3,4,5,6</sup> It is proposed that these drugs upregulate the enzymes responsible for vitamin D metabolism, resulting in the conversion of 25-hydroxyvitamin D into inactive metabolites.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc; March 2010.</p>\n<p>2. Hamed SA. Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs. <i>Expert Rev Clin Pharmacol</i>. 2016;9(2):267-286. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26589104\">[PubMed 26589104]</a></p>\n<p>3. Zerwekh JE, Homan R, Tindall R, et al. Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics. <i>Ann Neurol</i>. 1982;12(2):184-186. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6982022\">[PubMed 6982022]</a></p>\n<p>4. Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. <i>Q J Med</i>. 1986;59(230):569-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3092278\">[PubMed 3092278]</a></p>\n<p>5. Wang Z, Lin YS, Dickmann LJ, et al. Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. <i>J Bone Miner Res</i>. 2013;28(5):1101-1116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23212742\">[PubMed 23212742]</a></p>\n<p>6. de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. <i>Rev Psiquiatr Salud Ment</i>. 2015;8(2):97-115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25745819\">[PubMed 25745819]</a></p>\n<p>7. Meier C, Kraenzlin ME. Antiepileptics and bone health. <i>Ther Adv Musculoskelet Dis</i>. 2011;3(5):235-243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22870482\">[PubMed 22870482]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11234":"<p><b>Title</b> Entacapone / Iron Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Entacapone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa, which is always used with entacapone, during concomitant therapy, particularly if doses cannot be separated.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> The label for the combination carbidopa, levodopa and entacapone combination product does recommend caution with coadministration of iron due to the possibility that chelation may result in decreased bioavailability of levodopa, carbidopa, and entacapone.<sup>1</sup> The prescribing information for the single entity entacapone product also does state that entacapone is a chelator of iron, but the label does not specifically warn about a potential drug-drug interaction or provide any recommendation about separating administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stalevo (carbidopa, levodopa and entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2016.</p>\n<p>2. Comtan (entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11235":"<p><b>Title</b> Thyroid Products / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may diminish the therapeutic effect of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of hypothyroidism in patients taking thyroid products with ritonavir. Increases in thyroid product doses or discontinuation of ritonavir may be required to achieve a euthyroid state.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> A case report describes a 58-year-old woman taking zidovudine, lamivudine, and lopinavir/ritonavir who was initiated on levothyroxine.<sup>1</sup> Despite increasing doses of levothyroxine (up to 225 mcg daily) she remained persistently hypothyroid with elevated thyroid stimulating hormone (TSH) levels and decreased free T4 concentrations.<sup>1</sup> Two months after withdrawal of her antiretroviral therapy, her TSH and T4 concentrations normalized.<sup>1</sup> Eight months later, due to a decreasing CD4 cell count, her antiretroviral therapy was reintroduced and she again developed hypothyroidism.<sup>1</sup> Her TSH and T4 concentrations normalized after lopinavir/ritonavir was switched to abacavir.<sup>1</sup> Another case report describes a 37-year-old woman taking abacavir, lamivudine, and lopinavir/ritonavir who was initiated on levothyroxine (75 mcg daily).<sup>2</sup> Despite increasing the dose of levothyroxine up to 175 mcg daily, her TSH remained elevated and she continued to have symptoms of hypothyroidism.<sup>2</sup> A change from lopinavir/ritonavir to darunavir/ritonavir did not improve her hypothyroidism, but her TSH normalized after darunavir/ritonavir was switched to dolutegravir.<sup>2</sup> Another report describes a 29-year-old man taking lamivudine, zidovudine, and saquinavir who was initiated on levothyroxine (125 mcg daily) for the treatment of hypothyroidism.<sup>3</sup> He became euthyroid and was stable on his medication regimen for 1 year. Due to an increase in his HIV viral load, his antiretroviral regimen was changed to stavudine, lamivudine, saquinavir, and ritonavir.<sup>3</sup> One month later, the patient had an elevated TSH and symptoms of lethargy. His levothyroxine dose was gradually increased and he finally achieved a euthyroid state with a levothyroxine dose of 250 mcg daily. When ritonavir was discontinued and his antiretroviral regimen was subsequently changed to stavudine, lamivudine, and indinavir, he required a levothyroxine dose reduction back to 125 mcg daily.<sup>3</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but ritonavir-mediated induction of uridine diphosphate glucuronosyltransferases (UGTs), enzymes responsible for levothyroxine metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Touzot M, Beller CL, Touzot F, Louet AL, Piketty C. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient. <i>AIDS</i>. 2006;20(8):1210-1212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16691080\">[PubMed 16691080]</a></p>\n<p>2. Sahajpal R, Ahmed RA, Hughes CA, Foisy MM. Probable interaction between levothyroxine and ritonavir: case report and literature review. <i>Am J Health Syst Pharm</i>. 2017;74(8):587-592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28389458\">[PubMed 28389458]</a></p>\n<p>3. Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine. <i>AIDS</i>. 1998;12(16):2235-2236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9833871\">[PubMed 9833871]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11236":"<p><b>Title</b> Rivaroxaban / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Rivaroxaban. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the combined use of cobicistat and rivaroxaban due to a possible increase in rivaroxaban concentrations and effects (eg, bleeding, bruising) when the drugs are used concomitantly.</p> \n<p><b>Discussion</b> A case report describes a 69-year-old man with normal renal function taking elvitegravir/cobicistat, emtricitabine, and tenofovir disoproxil fumarate who was started on rivaroxaban 20 mg daily for the treatment of atrial fibrillation.<sup>1</sup> Two months later, he reported extensive bruising on his left thigh from a minor injury. Laboratory tests revealed an elevated rivaroxaban concentration of 210 ng/mL (predicted concentration from simulated pharmacokinetic modeling was 75 ng/mL).<sup>1</sup> After elvitegravir/cobicistat was replaced with dolutegravir, the rivaroxaban concentration decreased to 93 ng/mL, the anti-factor Xa concentration decreased 64% (193.8 to 70.7), and the patient reported no additional bruising or bleeding events.<sup>1</sup><br><br>The cobicistat product labeling states that the concomitant use of cobicistat and rivaroxaban should be avoided due to a possible increase in rivaroxaban concentrations and effects when the drugs are used concomitantly.<sup>2</sup><br><br>The mechanism of this interaction is likely due to cobicistat-mediated inhibition of CYP3A4, an enzyme responsible for rivaroxaban metabolism. Cobicistat-mediated inhibition of P-glycoprotein may have also contributed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yoong D, Naccarato M, Gough K. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir [published online March 1, 2017]. <i>Ann Pharmacother</i>. doi:10.1177/1060028017702677. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28351160\">[PubMed 28351160]</a></p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11237":"<p><b>Title</b> Danthron / Docusate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Docusate may increase the absorption of Danthron. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The labeling for danthron-poloxamer 188 states that concurrent use with a stool softener, such as docusate, may result in increased systemic absorption of danthron.<sup>1</sup><br><br>Both the magnitude and clinical significance of this reported interaction are uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Strong Co-Danthramer (danthron-poloxamer 188) [UK summary of product characteristics]. Tipperary, United Kingdom: Pinewood Laboratories Limited; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11238":"<p><b>Title</b> Penicillins / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulfinpyrazone may increase the serum concentration of Penicillins. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Amoxicillin, Ampicillin, Bacampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Nafcillin, Oxacillin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Piperacillin, Temocillin, Ticarcillin</p>\n</div> \n<p><b>Discussion</b> Sulfinpyrazone has been shown to increase the half-life of penicillin G.<sup>1</sup> A pharmacokinetic study of 61 patients (sulfinpyrazone, n = 8 patients), showed that sulfinpyrazone in standard oral doses (600 mg/daily) prolonged the half-life of penicillin G by 65% (42.6 minutes vs. 70.3 minutes). Product labeling for sulfinpyrazone recognizes this potential interaction; however, no alternative recommendations or warnings are provided.<sup>2</sup><br><br>Sulfinpyrazone competes with penicillin for renal tubular excretion, and thus reduces the elimination of the penicillin.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kampmann J, Hansen JM, Siersboek-Nielsen K, et al. Effect of some drugs on penicillin half-life in blood. <i>Clin Pharmacol Ther</i>. 1972;13(4):516-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5042368\">[PubMed 5042368]</a></p>\n<p>2. Anturan (Sulfinpyrazone) tablet [summary of product characteristics]. London, United Kingdom: Amidpharm UK Limited; August 2016.</p>\n<p>3. Prescott LF. Pharmacokinetic drug interactions. <i>Lancet</i>. 1969;2(7632):1239-1243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4187823\">[PubMed 4187823]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11239":"<p><b>Title</b> Theophylline Derivatives / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfinpyrazone may decrease the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and reduced therapeutic effects of theophylline derivatives if sulfinpyrazone is administered concomitantly.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline<br><b>Exception</b> Dyphylline</p>\n</div> \n<p><b>Discussion</b> Sulfinpyrazone has been shown to increase plasma theophylline clearance.<sup>1</sup> In a pharmacokinetic study of 6 healthy, non-smoking male patients (ages 20 to 33 years), sulfinpyrazone in standard oral doses (800 mg/daily) increased plasma theophylline clearance by 22%, a sum of increases in metabolic clearance and a decrease in renal clearance. The sulfinpyrazone product labeling acknowledges this interaction and states that serum theophylline concentrations may be reduced when theophylline is used in combination with sulfinpyrazone.<sup>2</sup><br><br>The mechanism of this interaction is likely due to activation of microsomal liver enzymes, resulting in increased theophylline metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Birkett DJ, Miners JO, Attwood J. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. <i>Br J Clin Pharmacol</i>. 1983;15(5):567-569. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6860533\">[PubMed 6860533]</a></p>\n<p>2. Anturan (Sulfinpyrazone) tablet [summary of product characteristics]. London, United Kingdom: Amidpharm UK Limited; August 2016.</p>\n<p>3. Walter E, Staiger C, de Vries J, et al. Induction of drug metabolizing enzymes by sulfinpyrazone. <i>Eur J Clin Pharmacol</i>. 1981;19(5):353-358. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6113147\">[PubMed 6113147]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11240":"<p><b>Title</b> Povidone-Iodine (Topical) / Taurolidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Taurolidine may enhance the adverse/toxic effect of Povidone-Iodine (Topical). Specifically, concomitant use of taurolidine and povidone-iodine may increase the risk of metabolic acidosis. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of taurolidine and povidone-iodine due to the increased risk for metabolic acidosis caused by this combination.</p> \n<p><b>Discussion</b> The taurolidine product labeling states that metabolic acidosis can occur with the coadministration of taurolidine and povidone-iodine.<sup>1,2</sup> There are no existing reports of a possible taurolidine and povidone-iodine interaction published in the English language. However, the taurolidine product labeling states that metabolic acidosis can occur with the coadministration of taurolidine and oxidizing agents including povidone-iodine, hydrogen peroxide, and Dakin’s solution (diluted sodium hypochlorite).<br><br>The mechanism for this potential interaction is likely related to oxidation-reduction chemical reactions and/or the accumulation of iodine leading to systemic toxicity.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Taurolin (taurolidine) [summary of product characteristics]. Dublin, Ireland: Allphar Services Limited; January 2015.</p>\n<p>2. Taurolin (taurolidine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198700927. Accessed October 24, 2014.</p>\n<p>3. Glick PL, Guglielmo BJ, Tranbaugh RF, et al. Iodine toxicity in a patient treated by continuous povidone-iodine mediastinal irrigation. <i>Ann Thorac Surg</i>. 1985;39(5):478-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3994451\">[PubMed 3994451]</a></p>\n<p>4. Racioppi F, Daskaleros PA, Besbelli N, et al. Household bleaches based on sodium hypochlorite: review of acute toxicology and poison control center experience. <i>Food Chem Toxicol</i>. 1994;32(9):845-861. [Pub Med 7927083]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11241":"<p><b>Title</b> Hydrogen Peroxide / Taurolidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Taurolidine may enhance the adverse/toxic effect of Hydrogen Peroxide. Specifically, concomitant use of taurolidine and hydrogen peroxide may increase the risk of metabolic acidosis. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of taurolidine and hydrogen peroxide due to the increased risk for metabolic acidosis caused by this combination.</p> \n<p><b>Discussion</b> The taurolidine product labeling states that metabolic acidosis can occur with the coadministration of taurolidine and hydrogen peroxide.<sup>1,2</sup> There are no existing reports of a possible taurolidine-hydrogen peroxide interaction published in the English language. However, the taurolidine product labeling states that metabolic acidosis can occur with the coadministration of taurolidine and oxidizing agents including hydrogen peroxide, povidone iodine, and Dakin’s solution (diluted sodium hypochlorite).<br><br>The mechanism for this potential interaction is likely related to oxidation-reduction chemical reactions and/or the accumulation of iodine leading to systemic toxicity.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Taurolin (taurolidine) [summary of product characteristics]. Dublin, Ireland: Allphar Services Limited; January 2015.</p>\n<p>2. Taurolin (taurolidine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198700927. Accessed October 24, 2014.</p>\n<p>3. Glick PL, Guglielmo BJ, Tranbaugh RF, et al. Iodine toxicity in a patient treated by continuous povidone-iodine mediastinal irrigation. <i>Ann Thorac Surg</i>. 1985;39(5):478-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3994451\">[PubMed 3994451]</a></p>\n<p>4. Racioppi F, Daskaleros PA, Besbelli N, et al. Household bleaches based on sodium hypochlorite: review of acute toxicology and poison control center experience. <i>Food Chem Toxicol</i>. 1994;32(9):845-861. [Pub Med 7927083]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11242":"<p><b>Title</b> Sodium Hypochlorite / Taurolidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Taurolidine may enhance the adverse/toxic effect of Sodium Hypochlorite. Specifically, concomitant use of taurolidine and sodium hypochlorite may increase the risk of metabolic acidosis. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of taurolidine and sodium hypochlorite due to the increased risk for metabolic acidosis caused by this combination.</p> \n<p><b>Discussion</b> The taurolidine product labeling states that metabolic acidosis can occur with the coadministration of taurolidine and diluted sodium hypochlorite (Dakin's solution).<sup>1,2</sup> There are no existing reports of a possible taurolidine-sodium hypochlorite interaction published in the English language. However, the taurolidine product labeling states that metabolic acidosis can occur with the coadministration of taurolidine and oxidizing agents including diluted sodium hypochlorite (Dakin's solution), povidone iodine, and hydrogen peroxide.<br><br>The mechanism for this potential interaction is likely related to oxidation-reduction chemical reactions and/or the accumulation of iodine leading to systemic toxicity.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Taurolin (taurolidine) [summary of product characteristics]. Dublin, Ireland: Allphar Services Limited; January 2015.</p>\n<p>2. Taurolin (taurolidine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198700927. Accessed October 24, 2014.</p>\n<p>3. Glick PL, Guglielmo BJ, Tranbaugh RF, et al. Iodine toxicity in a patient treated by continuous povidone-iodine mediastinal irrigation. <i>Ann Thorac Surg</i>. 1985;39(5):478-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3994451\">[PubMed 3994451]</a></p>\n<p>4. Racioppi F, Daskaleros PA, Besbelli N, et al. Household bleaches based on sodium hypochlorite: review of acute toxicology and poison control center experience. <i>Food Chem Toxicol</i>. 1994;32(9):845-861. [Pub Med 7927083]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11243":"<p><b>Title</b> Midostaurin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions, especially during the first week of consecutive midostaurin administration in the advanced systemic mastocytosis (SM) population, and during first week of midostaurin administration in each cycle of chemotherapy in the acute myeloid leukemia (AML) population</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in healthy volunteers, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 10 days) and midostaurin (50 mg single dose given on day 6) resulted in a midostaurin AUC and maximum serum concentration that were 10.4-fold and 1.8-fold higher, respectively, than when midostaurin was combined with placebo.<sup>1</sup> The AUC of the CGP62221 active metabolite was 3.5-fold higher and the AUC of the CGP52421 active metabolite was 1.2-fold higher with ketoconazole coadministration.<sup>1</sup> In another pharmacokinetic study described in the midostaurin prescribing information, coadministration of itraconazole (100 mg twice daily on Days 22 to 28 for 13 doses) with multiple doses of midostaurin (100 mg twice daily on Days 1 to 2 and 50 mg twice daily on Days 3 to 28) increased the day 28 minimum serum concentrations (Cmin) midostaurin by 2.1-fold, CGP62221 by 1.2-fold, and CGP52421 by 1.3-fold compared with the respective day 21 Cmin concentrations seen with midostaurin alone.<sup>2</sup><br><br>The midostaurin prescribing information states that because coadministration with strong CYP3A4 inhibitors may increase midostaurin exposure and lead to increased toxicities, clinicians should seek alternatives to the combined use of midostaurin and strong CYP3A4 inhibitors if possible.<sup>2</sup> If combined, patients should be monitored closely for increased toxicities, especially during the first week of consecutive midostaurin administration in the advanced SM population, and during first week of midostaurin administration in each cycle of chemotherapy in the AML population.<br><br>The mechanism of this interaction is likely ketoconazole- and itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for midostaurin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;72(6):1223-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24085261\">[PubMed 24085261]</a></p>\n<p>2. Rydapt (midostaurin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11244":"<p><b>Title</b> Midostaurin / Conivaptan</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of Midostaurin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of midostaurin and conivaptan if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions, especially during the first week of consecutive midostaurin administration in the advanced systemic mastocytosis (SM) population, and during first week of midostaurin administration in each cycle of chemotherapy in the acute myeloid leukemia (AML) population</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in healthy volunteers, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 10 days) and midostaurin (50 mg single dose given on day 6) resulted in a midostaurin AUC and maximum serum concentration that were 10.4-fold and 1.8-fold higher, respectively, than when midostaurin was combined with placebo.<sup>1</sup> The AUC of the CGP62221 active metabolite was 3.5-fold higher and the AUC of the CGP52421 active metabolite was 1.2-fold higher with ketoconazole coadministration.<sup>1</sup> In another pharmacokinetic study described in the midostaurin prescribing information, coadministration of itraconazole (100 mg twice daily on Days 22 to 28 for 13 doses) with multiple doses of midostaurin (100 mg twice daily on Days 1 to 2 and 50 mg twice daily on Days 3 to 28) increased the day 28 minimum serum concentrations (Cmin) midostaurin by 2.1-fold, CGP62221 by 1.2-fold, and CGP52421 by 1.3-fold compared with the respective day 21 Cmin concentrations seen with midostaurin alone.<sup>2</sup><br><br>The midostaurin prescribing information states that because coadministration with strong CYP3A4 inhibitors may increase midostaurin exposure and lead to increased toxicities, clinicians should seek alternatives to the combined use of midostaurin and strong CYP3A4 inhibitors if possible.<sup>2</sup> If combined, patients should be monitored closely for increased toxicities, especially during the first week of consecutive midostaurin administration in the advanced SM population, and during first week of midostaurin administration in each cycle of chemotherapy in the AML population. Although typically considered moderate CYP3A4 inhibitors, the midostaurin prescribing information lists conivaptan, diltiazem, and grapefruit juice as agents that should also be avoided if possible.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole- and itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for midostaurin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;72(6):1223-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24085261\">[PubMed 24085261]</a></p>\n<p>2. Rydapt (midostaurin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11245":"<p><b>Title</b> Midostaurin / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> DilTIAZem may increase the serum concentration of Midostaurin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of midostaurin and diltiazem if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions, especially during the first week of consecutive midostaurin administration in the advanced systemic mastocytosis (SM) population, and during first week of midostaurin administration in each cycle of chemotherapy in the acute myeloid leukemia (AML) population.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in healthy volunteers, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 10 days) and midostaurin (50 mg single dose given on day 6) resulted in a midostaurin AUC and maximum serum concentration that were 10.4-fold and 1.8-fold higher, respectively, than when midostaurin was combined with placebo.<sup>1</sup> The AUC of the CGP62221 active metabolite was 3.5-fold higher and the AUC of the CGP52421 active metabolite was 1.2-fold higher with ketoconazole coadministration.<sup>1</sup> In another pharmacokinetic study described in the midostaurin prescribing information, coadministration of itraconazole (100 mg twice daily on Days 22 to 28 for 13 doses) with multiple doses of midostaurin (100 mg twice daily on Days 1 to 2 and 50 mg twice daily on Days 3 to 28) increased the day 28 minimum serum concentrations (Cmin) midostaurin by 2.1-fold, CGP62221 by 1.2-fold, and CGP52421 by 1.3-fold compared with the respective day 21 Cmin concentrations seen with midostaurin alone.<sup>2</sup><br><br>The midostaurin prescribing information states that because coadministration with strong CYP3A4 inhibitors may increase midostaurin exposure and lead to increased toxicities, clinicians should seek alternatives to the combined use of midostaurin and strong CYP3A4 inhibitors if possible.<sup>2</sup> If combined, patients should be monitored closely for increased toxicities, especially during the first week of consecutive midostaurin administration in the advanced SM population, and during first week of midostaurin administration in each cycle of chemotherapy in the AML population. Although typically considered moderate CYP3A4 inhibitors, the midostaurin prescribing information lists conivaptan, diltiazem, and grapefruit juice as agents that should also be avoided if possible.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole- and itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for midostaurin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;72(6):1223-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24085261\">[PubMed 24085261]</a></p>\n<p>2. Rydapt (midostaurin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11246":"<p><b>Title</b> Midostaurin / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Midostaurin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of midostaurin and grapefruit juice if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions, especially during the first week of consecutive midostaurin administration in the advanced systemic mastocytosis (SM) population, and during first week of midostaurin administration in each cycle of chemotherapy in the acute myeloid leukemia (AML) population.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in healthy volunteers, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 10 days) and midostaurin (50 mg single dose given on day 6) resulted in a midostaurin AUC and maximum serum concentration that were 10.4-fold and 1.8-fold higher, respectively, than when midostaurin was combined with placebo.<sup>1</sup> The AUC of the CGP62221 active metabolite was 3.5-fold higher and the AUC of the CGP52421 active metabolite was 1.2-fold higher with ketoconazole coadministration.<sup>1</sup> In another pharmacokinetic study described in the midostaurin prescribing information, coadministration of itraconazole (100 mg twice daily on Days 22 to 28 for 13 doses) with multiple doses of midostaurin (100 mg twice daily on Days 1 to 2 and 50 mg twice daily on Days 3 to 28) increased the day 28 minimum serum concentrations (Cmin) midostaurin by 2.1-fold, CGP62221 by 1.2-fold, and CGP52421 by 1.3-fold compared with the respective day 21 Cmin concentrations seen with midostaurin alone.<sup>2</sup><br><br>The midostaurin prescribing information states that because coadministration with strong CYP3A4 inhibitors may increase midostaurin exposure and lead to increased toxicities, clinicians should seek alternatives to the combined use of midostaurin and strong CYP3A4 inhibitors if possible.<sup>2</sup> If combined, patients should be monitored closely for increased toxicities, especially during the first week of consecutive midostaurin administration in the advanced SM population, and during first week of midostaurin administration in each cycle of chemotherapy in the AML population. Although typically considered moderate CYP3A4 inhibitors, the midostaurin prescribing information lists conivaptan, diltiazem, and grapefruit juice as agents that should also be avoided if possible.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole- and itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for midostaurin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;72(6):1223-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24085261\">[PubMed 24085261]</a></p>\n<p>2. Rydapt (midostaurin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11247":"<p><b>Title</b> Midostaurin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of midostaurin and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in healthy volunteers, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily x 14 days) and midostaurin (50 mg single dose given on day 9) resulted in a midostaurin AUC and maximum serum concentration that were 94% and 73% lower, respectively, than when midostaurin was combined with placebo.<sup>1</sup> The AUC of the CGP62221 active metabolite was 92% lower and the AUC of the CGP52421 active metabolite was 59% lower with rifampin coadministration.<sup>1</sup><br><br>The midostaurin prescribing information states that because coadministration with strong CYP3A4 inducers may reduce midostaurin exposure and lead to reduced efficacy, the combined use of midostaurin and strong CYP3A4 inducers should be avoided.<sup>2</sup><br><br>The mechanism of this interaction is likely rifampin-mediated induction of CYP3A4, an enzyme responsible for midostaurin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;72(6):1223-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24085261\">[PubMed 24085261]</a></p>\n<p>2. Rydapt (midostaurin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11248":"<p><b>Title</b> Midostaurin / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Midostaurin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of midostaurin and St. John's wort.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in healthy volunteers, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily x 14 days) and midostaurin (50 mg single dose given on day 9) resulted in a midostaurin AUC and maximum serum concentration that were 94% and 73% lower, respectively, than when midostaurin was combined with placebo.<sup>1</sup> The AUC of the CGP62221 active metabolite was 92% lower and the AUC of the CGP52421 active metabolite was 59% lower with rifampin coadministration.<sup>1</sup><br><br>The midostaurin prescribing information states that because coadministration with strong CYP3A4 inducers and St. John's wort may reduce midostaurin exposure and lead to reduced efficacy, the combined use of midostaurin and strong CYP3A4 inducers or St. John's wort should be avoided.<sup>2</sup><br><br>The mechanism of this interaction is likely rifampin-mediated induction of CYP3A4, an enzyme responsible for midostaurin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;72(6):1223-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24085261\">[PubMed 24085261]</a></p>\n<p>2. Rydapt (midostaurin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11253":"<p><b>Title</b> Clindamycin (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Clindamycin (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required, but increased exposure to clindamycin may result from concomitant use.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The clindamycin prescribing information states that because clindamycin is primarily metabolized by CYP3A4, concomitant use with inhibitors of CYP3A4 may increase clindamycin plasma concentrations.<sup>1</sup> Although no studies have evaluated the potential impact of strong CYP3A4 inhibitors on clindamycin concentrations, clindamycin prescribing information states that adverse reactions may occur when these agents are combined.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cleocin (clindamycin) [prescribing information]. New York, NY: Pfizer Inc; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11254":"<p><b>Title</b> Digoxin / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may decrease the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased digoxin concentrations if combined with bupropion.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the digoxin (0.5 mg single oral dose) AUC was 60% lower and the renal clearance was 80% higher in patients who received a single dose of extended release bupropion (150 mg) 24 hours prior to digoxin administration (n = 9) compared with the digoxin AUC and renal clearance in patients who received digoxin alone (n = 11).<sup>1</sup><br><br>Bupropion prescribing information states that coadministration of bupropion and digoxin may lead to decreased digoxin exposure, and digoxin plasma concentrations should be monitored during concomitant use.<sup>2,3</sup><br><br>The mechanism of this interaction has not been fully investigated, but bupropion-mediated stimulation/induction of OATP4C1, a transporter located on the basolateral membrane of the kidney that is involved in digoxin renal elimination, may play a role.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. <i>Drug Metab Dispos</i>. 2012;40(3):610-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190694\">[PubMed 22190694]</a></p>\n<p>2. Zyban (bupropion) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2017. </p>\n<p>3. Contrave (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; May 2017. </p>\n<p>4. He J, Yu Y, Prasad B, Chen X, Unadkat JD. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction. <i>Biopharm Drug Dispos</i>. 2014;35(5):253-263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24436229\">[PubMed 24436229]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11255":"<p><b>Title</b> Brigatinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg). Monitor patient closely for evidence of adverse effects with any use of this combination. After discontinuation of the strong CYP3A4 inhibitor, resume the dose tolerated prior to initiation of the strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The brigatinib AUC was increased by an average of 101% with concurrent administration of the strong CYP3A4 inhibitor itraconazole in a study where subjects received a single dose of brigatinib (90 mg) with itraconazole (200 mg twice daily).<sup>1</sup><br><br>The likely mechanism for this interaction is itraconazole inhibition of the CYP3A4 metabolism of brigatinib.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11256":"<p><b>Title</b> Brigatinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Brigatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of brigatinib with grapefruit juice or grapefruit.</p> \n<p><b>Discussion</b> Specific data with concurrent grapefruit juice are not available, but the brigatinib AUC was increased by an average of 101% with concurrent administration of the strong CYP3A4 inhibitor itraconazole in a study where subjects received a single dose of brigatinib (90 mg) with itraconazole (200 mg twice daily).<sup>1</sup> Grapefruit juice is more of a moderate CYP3A4 inhibitor, but the brigatinib prescribing information specifically recommends avoiding grapefruit juice or grapefruit with brigatinib.<br><br>The suspected mechanism for this likely interaction is inhibition of the CYP3A4-mediated metabolism of brigatinib by grapefruit.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11257":"<p><b>Title</b> Brigatinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of brigatinib with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The brigatinib AUC was decreased by an average of 80% with concurrent administration of the strong CYP3A4 inducer rifampin in a study where subjects received a single dose of brigatinib (180 mg) with rifampin (600 mg daily).<sup>1</sup><br><br>The suspected mechanism for this likely interaction is induction of the CYP3A4-mediated metabolism of brigatinib by rifampin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11258":"<p><b>Title</b> Brigatinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Brigatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of brigatinib with St John's Wort.</p> \n<p><b>Discussion</b> Specific data with concurrent St John's Wort (SJW) are not available, but the brigatinib AUC was decreased by an average of 80% with concurrent administration of the strong CYP3A4 inducer rifampin in a study where subjects received a single dose of brigatinib (180 mg) with rifampin (600 mg daily).<sup>1</sup> SJW is more of a moderate CYP3A4 inducer, but the brigatinib prescribing information specifically recommends avoiding SJW with brigatinib.<br><br>The suspected mechanism for this likely interaction is induction of the CYP3A4-mediated metabolism of brigatinib by SJW.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11259":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Brigatinib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Brigatinib may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Specific data with hormonal contraceptives are not available, but the brigatinib prescribing information recommends use of an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose due to observations that brigatinib has been shown to be a CYP3A4 inducer in vitro.<sup>1</sup><br><br>The suspected mechanism for this possible interaction is induction of the CYP3A4-mediated metabolism of estrogen or progestin contraceptives by brigatinib.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11260":"<p><b>Title</b> Progestins (Contraceptive) / Brigatinib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Brigatinib may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Specific data with hormonal contraceptives are not available, but the brigatinib prescribing information recommends use of an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose due to observations that brigatinib has been shown to be a CYP3A4 inducer in vitro.<sup>1</sup><br><br>The suspected mechanism for this possible interaction is induction of the CYP3A4-mediated metabolism of estrogen or progestin contraceptives by brigatinib.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11261":"<p><b>Title</b> Antihypertensive Agents / Brigatinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Brigatinib may diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of decreased response to antihypertensive medications with concurrent use of brigatinib, and monitor patients closely for evidence of clinically relevant bradycardia with use of antihypertensives that can also cause bradycardia.</p>\n<div>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Brigatinib has been shown to cause hypertension in 11% of patients at a dose of 90 mg and in 21% of patients increased from 90 mg to 180 mg.<sup>1</sup> The mechanism by which brigatinib increases blood pressure is unknown as is the extent to which it could alter the effectiveness of antihypertensive therapy.<br><br>Between 5.7% and 7.6% of patients receiving brigatinib experienced heart rates below 50 bpm, and the brigatinib label recommends closer monitoring if concurrent use of brigatinib with bradycardia-causing drugs cannot be avoided.<sup>1</sup> Antihypertensives that are capable of causing bradycardia should be used with caution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11262":"<p><b>Title</b> Temsirolimus / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider increasing the dose of temsirolimus to 50 mg IV/week (from 25 mg IV/week) if a concomitant CYP3A4 strong inducer is necessary. Monitor adverse effects and serum concentrations of sirolimus (active metabolite) with the combination of temsirolimus and a CYP3A4 strong inducer. If the strong CYP3A4 inducer is discontinued, decrease temsirolimus to the dose used prior to the initiation of the CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The co-administration of temsirolimus and a strong CYP3A4 inducer is not recommended by the manufacturer.<sup>1</sup> However, if such an inducer is indicated, an increased dose of 50 mg IV/week (from 25 mg IV/week) of temsirolimus is warranted.<sup>1</sup> This dosage adjustment has not been clinically evaluated; rather, it is based on the extrapolation of pharmacokinetic data to predict temsirolimus and sirolimus pharmacokinerics without an interacting agent.<sup>1,2,3</sup><br><br>Temsirolimus and sirolimus (active metabolite) pharmacokinetic parameters decreased when a strong CYP3A4 inducer, phenytoin (n=6) or carbamazepine (n=5), was administered concomitantly in patients with malignant gliomas or brain metastases from solid tumors.<sup>2</sup> Temsirolimus AUC and maximum serum concentration (Cmax) were approximately 15% and 36% less than when receiving temsirolimus alone. The AUC and Cmax of the active metabolite, sirolimus, measured even lower (43% and 67% less). <sup>2</sup> The strong CYP3A4 inducer rifampin had a substantially greater impact on temsirolimus pharmacokinetics following oral temsirolimus, but a similar magnitude of effect on sirolimus pharmacokinetics regardless of the route of temsirolimus administration.<sup>2</sup> Concurrent rifampin (600mg daily) was associated with 41% and 30% reductions in temsirolimus Cmax and AUC following oral temsirolimus (30mg), but only negligible (less than 10%) changes in temsirolimus Cmax and AUC following intravenous temsirolimus (25mg). Conversely, decreases in sirolimus Cmax and AUC were similar following either oral (63% and 60%, respectively) or intravenous (65% and 56%, respectively) temsirolimus administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc.; July 2016.</p>\n<p>2. Boni J, Leister C, Burns J, et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. <i>J Clin Pharmacol</i>. 2007;47:1430-1439. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p>3. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. <i> AAPS J</i>. 2004;6(4):1-12 . <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15760093\">[PubMed 15760093]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11263":"<p><b>Title</b> Temsirolimus / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors whenever possible. If combined, decrease temsirolimus dose to 12.5 mg per week and monitor patients for increased temsirolimus effects and toxicities. Once the strong CYP3A4 inhibitor is discontinued, a washout period of approximately 1 week should be allowed before the temsirolimus dose is adjusted back to the dose used prior to initiation of the strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In 17 healthy subjects, the coadministration of IV temsirolimus (5 mg single dose) with oral ketoconazole (400 mg daily for 7 days) had no effect on temsirolimus AUC or maximum serum concentration (Cmax).<sup>1</sup> Although temsirolimus pharmacokinetics were not affected, the AUC and Cmax of sirolimus (the primary active temsirolimus metabolite) increased 3.1-fold and 2.2-fold, respectively.<sup>1</sup> Numerous studies and case reports have evaluated the effect of strong CYP3A4 inhibitors on the pharmacokinetics of oral sirolimus and all have reported increases in sirolimus AUC and support dose reduction strategies.<sup>2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22</sup> The AUC increases appears more profound with oral sirolimus compared with IV temsirolimus, likely due to ketoconazole-mediated CYP3A4 inhibition in the gastrointestinal epithelium, leading to enhanced first-pass absorption of sirolimus.<sup>1</sup><br><br>Temsirolimus prescribing information states that concomitant use of strong CYP3A4 inhibitors should be avoided if possible.<sup>23</sup> If combined, a dose reduction of temsirolimus to 12.5 mg per week should be considered.<sup>23</sup> This dose reduction is based on pharmacokinetic studies, but there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inhibitors. If the strong CYP3A4 inhibitor is discontinued, a washout period of 1 week is recommended before adjusting back to the dose prior to strong CYP3A4 inhibitor inititation.<sup>23</sup><br><br>The mechanism of this interaction is likely due to CYP3A4 inhibition, the enzyme responsible for temsirolimus (and sirolimus) metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boni JP, Leister C, Burns J, Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. <i>Br J Cancer</i>. 2008;98(11):1797-1802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18458675\">[PubMed 18458675]</a></p>\n<p>2. Greco R, Barbanti MC, Lupo Stranghellini MT, et al. Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplant</i>. 2016;51(7):1022-1024. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27111047\">[PubMed 27111047]</a></p>\n<p>3. Cho E, Chan H, Nguyen HM, Shayani S, Nakamura R, Pon D. Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. <i>Pharmacotherapy</i>. 2015;35(6):578-585. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26037821\">[PubMed 26037821]</a></p>\n<p>4. Ceberio I, Dai K, Devlin SM, et al. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. <i>Bone Marrow Transplant</i>. 2015;50(3):438-443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25599164\">[PubMed 25599164]</a></p>\n<p>5. Peksa GD, Schultz K, Fung HC. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. <i>J Oncol Pharm Pract</i>. 2015;21(6):409-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24938293\">[PubMed 24938293]</a></p>\n<p>6. O’Leary JG, McKenna GJ, Klintmalm GB, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. <i>Liver Transpl</i>. 2013;19(4):463-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23408534\">[PubMed 23408534]</a></p>\n<p>7. Cohen EE, Wu K, Hartford C, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. <i>Clin Cancer Res</i>. 2012;18(17):4785-4793. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22872575\">[PubMed 22872575]</a></p>\n<p>8. Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. <i>Liver Transpl</i>. 2012;18(12):1464-1470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22941516\">[PubMed 22941516]</a></p>\n<p>9. Kubiak DW, Koo S, Hammond SP, et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. <i>Biol Blood Marrow Transplant</i>. 2012;18(9):1462-1465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22564264\">[PubMed 22564264]</a></p>\n<p>10. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. <i>Curr Med Res Opin</i>. 2009;25(3):701-707. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19196220\">[PubMed 19196220]</a> </p>\n<p>11. Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. <i>Pharmacotherapy</i>. 2008;28(6):719-729. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18503400\">[PubMed 18503400]</a></p>\n<p>12. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2006;12(5):552-559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16635790\">[PubMed 16635790]</a></p>\n<p>13. Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. <i>Transplantation</i>. 2004;77(3):474-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14966432\">[PubMed 14966432]</a></p>\n<p>14. Petitcollin A, Crochette R, Tron C, et al. Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole. <i>Drug Metab Pharmacokinet</i>. 2016;31(5):389-393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27530708\">[PubMed 27530708]</a></p>\n<p>15. Dahlan R, Patel A, Haider S. Successful use of posaconazole to treat invasive cutaneous fungal infection in a liver transplant patient on sirolimus. <i>Can J Infect Dis Med Microbiol</i>. 2012;23(2):e44-e47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23730320\">[PubMed 23730320]</a></p>\n<p>16. Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. <i>Fundam Clin Pharmacol</i>. 2009;23(4):423-425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19709321\">[PubMed 19709321]</a></p>\n<p>17. Capone D, Palmiero G, Gentile A, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. <i>Curr Drug Metab</i>. 2007;8(4):379-381. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17504225\">[PubMed 17504225]</a></p>\n<p>18. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. <i>Pharmacotherapy</i>. 2006;26(2):289-295. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466336\">[PubMed 16466336]</a></p>\n<p>19. Kuypers DR, Claes K, Evenepoel P, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. <i>Transplantation</i>. 2005;79(6):737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15785385\">[PubMed 15785385]</a></p>\n<p>20. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. <i>Transplant Proc</i>. 2004;36(10):3226-3228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15686733\">[PubMed 15686733]</a></p>\n<p>21. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. <i>Transplant Proc</i>. 2004;36(9):2708-2709. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15621130\">[PubMed 15621130]</a></p>\n<p>22. Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. <i>Liver Transpl</i>. 2002;8(9):838-840. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12200787\">[PubMed 12200787]</a></p>\n<p>23. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11264":"<p><b>Title</b> Sirolimus / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DilTIAZem may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor sirolimus concentrations closely as well as signs and symptoms of sirolimus adverse effects (eg, hyperlipidemia, thrombocytopenia, and leukopenia) if sirolimus and diltiazem are concurrently administered. Sirolimus dosing adjustments may be warranted.</p> \n<p><b>Discussion</b> Co-administration of diltiazem and sirolimus should be used with caution as the pharmacokinetics of sirolimus were significantly increased with combined use of these two agents.<sup>1</sup> A known substrate and inhibitor of CYP3A4, diltiazem (120 mg single dose) increased sirolimus (10 mg single dose) AUC and maximum serum concentration by an average of 1.6- and 1.4-fold, respectively, in a study of 18 healthy volunteers.<sup>2</sup> Conversely, diltiazem pharmacokinetics were not affected by sirolimus.<sup>2</sup> A higher number of side effects were reported when diltiazem and sirolimus were administered together versus alone, but none were noted as serious adverse effects.<sup>1</sup> Multiple dosing may elicit more serious effects from sirolimus.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc.; April 2017.</p>\n<p>2. Bottiger Y, Sawe J, Brattstrom C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2001;69:32-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180036\">[PubMed 11180036]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11265":"<p><b>Title</b> Sirolimus / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Sirolimus labeling states that grapefruit juice must not be taken with or used to dilute sirolimus.</p> \n<p><b>Discussion</b> Current labeling does not recommend the concomitant administration of (or dilution with) grapefruit juice (GFJ) and sirolimus due to the potential for GFJ to inhibit sirolimus metabolism by CYP3A4.<sup>1</sup> Although GFJ is a moderate CYP3A4 inhibitor, it has shown to significantly increase sirolimus AUC values by 350%.<sup>1,2</sup> In a Phase 1 study, sirolimus pharmacokinetics were evaluated in 101 patients with advanced cancer by administering GFJ as a booster of sirolimus concentrations for therapeutic use. Sirolimus doses of 15 mg to 30 mg weekly demonstrated maximum serum concentrations and AUC values ranging from 20% to 154% and 33% to 408%, respectively.<sup>2</sup> Hyperglycemia, hyperlipidemia, and lymphopenia were reported in 52%, 43%, and 41% of subjects, and 13 of them (from 138 subjects enrolled) experienced a grade 3 or 4 toxicity.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc.; April 2017.</p>\n<p>2. Cohen EEW, Wu K, Hartford C, et al. Phase 1 studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. <i>Clin Cancer Res</i>. 2012;18(17):4785-4793. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22872575\">[PubMed 22872575]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11266":"<p><b>Title</b> Verapamil / Sirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of Sirolimus. Sirolimus may increase the serum concentration of Verapamil. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor sirolimus concentrations when concurrent verapamil is administered. Dose adjustments may be necessary. Adverse effects of sirolimus, such as hyperglycemia, hyperlipidemia, and lymphopenia may occur in patients taking sirolimus and verapamil simultaneously. Blood pressure and other cardiovascular symptoms should also be monitored as verapamil concentrations may also increase with concurrent therapy.</p> \n<p><b>Discussion</b> Sirolimus and verapamil co-administration significantly increased sirolimus maximum serum concentration (Cmax) and AUC by 2.3- and 2.2-fold, respectively, in 26 subjects who were administered sirolimus 2 mg daily and verapamil 180 mg every 12 hours.<sup>1</sup> The Cmax and AUC of the S(-) enantiomer of verapamil also increased by 1.5-fold with concurrent sirolimus.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc.; April 2017.</p>\n<p>2. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. <i>AAPS J</i>. 2004;6(4):1-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15760093\">[PubMed 15760093]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11267":"<p><b>Title</b> Mometasone (Nasal) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Nasal). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of signs or symptoms of excessive corticosteroid response (ie, Cushing syndrome) if using nasal mometasone together with strong CYP3A4 inhibitors. Beclomethasone (and possibly some other steroids) may be less likely to have a clinically significant interaction; nasal fluticasone would <b>not</b> be a lower risk alternative.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Mometasone serum concentrations increased in 4 of 12 subjects from less than 150 pcg/mL to above 200 pcg/mL (range = 211 to 324 pcg/mL) with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of healthy subjects who received orally inhaled mometasone 400 mcg (by dry powder inhaler) for 9 days and ketoconazole 200 mg twice daily (on days 4 to 9).<sup>1,2</sup> The labeling for orally inhaled mometasone also states that plasma cortisol appeared to decrease with concurrent ketoconazole,<sup>1</sup> but the labeling for nasal mometasone does not contain this statement, despite summarizing the same pharmacokinetic changes from this study.<sup>2</sup><br><br>A case report describes a 9-year-old who was HIV-positive and experienced evidence of Cushing syndrome following the addition of orally inhaled fluticasone propionate (220 mcg) to a previously stable medication regimen that had included lopinavir/ritonavir (216 mg/54 mg twice daily) for 5 years and nasal mometasone for 11 months.<sup>3</sup> The role of nasal mometasone in this interaction is uncertain, although the timing of the patient's symptoms suggest an interaction between orally inhaled fluticasone and lopinavir/ritonavir is most responsible. That the patient did not have apparent problems despite 11 months of concurrent lopinavir/ritonavir and nasal mometasone may even suggest that this combination can be used safely in at least some patients.<br><br>Mometasone is metabolized to at least some degree by CYP3A4, so concurrent use with a strong CYP3A4 inhibitor is likely to increase mometasone concentrations. Both the magnitude and clinical significance of such an increase are unclear.<sup>1,2,4</sup><br><br>Whether alternative steroids would be of lower risk is uncertain. Labeling for the strong CYP3A4 inhibitor cobicistat specifically mentions beclomethasone as a safer alternative,<sup>5</sup> and a review article mentions beclomethasone among other steroids as options that are likely safer than fluticasone.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Asmanex HFA (mometasone) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; July 2016.</p>\n<p>2. Nasonex (mometasone) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2011.</p>\n<p>3. Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM. Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. <i>Ann Pharmacother</i>. 2007;41(7):1306-1309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17535841\">[PubMed 17535841]</a></p>\n<p>4. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. <i>Chest</i>. 2000;118(6):1538-1546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11115437\">[PubMed 11115437]</a></p>\n<p>5. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; May 2017.</p>\n<p>6. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. <i>HIV Med</i>. 2008;9(6):389-396. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18459946\">[PubMed 18459946]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11268":"<p><b>Title</b> Temsirolimus / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Grapefruit juice should be avoided with temsirolimus therapy.</p> \n<p><b>Discussion</b> Co-administration of temsirolimus with grapefruit juice is not recommended according to the prescribing information.<sup>1</sup> As temsirolimus is administered intravenously, the magnitude of this interaction is unclear as grapefruit juice would more likely affect intestinal CYP3A4 with little impact on hepatic CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Pfizer Inc., July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11276":"<p><b>Title</b> Potassium Citrate / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Solid oral dosage forms of potassium citrate are contraindicated in patients with impaired gastric emptying (eg, due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Agents with greater anticholinergic effects are likely of more concern than agents with lesser anticholinergic effects. Liquid or effervescent potassium preparations are possible alternatives.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Solid oral dosage forms of potassium citrate are contraindicated in patients with impaired gastric emptying (eg, due to the effects of drugs such as many anticholinergics) due to the risks of gastric and intestinal irritation and ulceration associated with prolonged contact between these solid dosage forms and the gastrointestinal mucosa.<sup>1</sup> Although there are no specific reports with potassium citrate, a publication describes an increased frequency and severity of gastrointestinal lesions following both wax-matrix and microencapsulated potassium chloride products amongst patients with slowed gastrointestinal motility due to the effects of anticholinergic drugs.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Urocit-K (potassium citrate) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; December 2009.</p>\n<p>2. McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. <i>Clin Pharmacol Ther</i>. 1984;35(6):852-855. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734038\">[PubMed 6734038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11277":"<p><b>Title</b> Digoxin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased digoxin serum concentrations and adjust digoxin dose as needed if cobicistat is coadministered with digoxin.</p> \n<p><b>Discussion</b> In a drug interaction study described in the cobicistat product labeling, cobicistat (150 mg daily) increased the digoxin (0.5 mg single dose) AUC and maximum serum concentration 8% and 41%, respectively, in 22 healthy volunteers.<sup>1</sup> The cobicistat product labeling states that because cobicistat increases serum digoxin concentrations, the digoxin dose should be titrated and serum digoxin concentrations monitored when digoxin is used in combination with cobicistat.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but cobicistat-mediated inhibition of P-glycoprotein may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc; May 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11278":"<p><b>Title</b> Dexibuprofen / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Dexibuprofen. Dexibuprofen may diminish the cardioprotective effect of Aspirin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid dexibuprofen in patients receiving aspirin or other nonsteroidal anti-inflammatory drugs.</p> \n<p><b>Discussion</b> The dexibuprofen labeling lists states that concurrent use with other nonsteroidal anti-inflammatory drugs or aspirin should be avoided due to a lack of evidence that aspirin may decrease the thrombotic cardiovascular reactions associated with nonsteroidal antiinflammatory drugs like dexibuprofen, and since these two agents may have a potential for additive side effects.<sup>1</sup> The labeling also suggests aspirin may interfere with the effects of ibuprofen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sonifen (dexibuprofen) [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201403363. Accessed March 15, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11279":"<p><b>Title</b> Dexibuprofen / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of dexibuprofen with any other nonsteroidal antiinflammatory agents should be avoided.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The dexibuprofen labeling cautions that use of dexibuprofen together with any other nonsteroidal antiinflammatory agent should be avoided due to a possible increased risk for gastrointestinal ulcers and bleeding.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sonifen (dexibuprofen) [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201403363. Accessed March 15, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11280":"<p><b>Title</b> Tacrolimus (Systemic) / Everolimus</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Everolimus may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In one pharmacokinetic study of 8 renal transplant patients treated with tacrolimus, mycophenolate mofetil (MMF), and corticosteroids, the discontinuation of MMF and the addition of everolimus (1.5 mg twice daily) did not affect any tacrolimus pharmacokinetic parameters.<sup>1</sup> In another pharmacokinetic analysis of 6 heart transplant recipients treated with tacrolimus and azathioprine, the discontinuation of azathioprine and the addition of everolimus (1.5 mg twice daily) had no effect on the pharmacokinetics of tacrolimus.<sup>2</sup><br><br>In contrast, one analysis reported that the tacrolimus oral clearance was 18% higher in patients who received a combination of tacrolimus and everolimus (1.5 mg twice daily) compared with patients who received a combination of tacrolimus and low-dose everolimus (0.75 mg twice daily).<sup>3</sup> Additionally, tacrolimus doses needed to maintain target trough levels were higher in patients who received the higher dose everolimus regimen (12.5 mg per day vs 9.5 mg per day).<sup>3</sup> However, because tacrolimus concentrations were not evaluated in the absence of everolimus and different groups of patients received different everolimus regimens, the contribution of everolimus to the observed differences in tacrolimus exposure is uncertain.<br><br>Lastly, in contrast to another calcineurin inhibitor cyclosporine, tacrolimus does not appear to affect the pharmacokinetics of everolimus.<sup>1,2,4</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. <i>Transplant Proc</i>. 2006;38(10):3456-3458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17175302\">[PubMed 17175302]</a></p>\n<p>2. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. <i>Ther Drug Monit</i>. 2008;30(1):113-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18223473\">[PubMed 18223473]</a></p>\n<p>3. Pascual J, del Castillo D, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. <i>Transplantation</i>. 2010;89(8):994-1000. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20335831\">[PubMed 20335831]</a></p>\n<p>4. Rostaing L, Christiaans MH, Kovarik JM, Pascual J. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. <i>Ann Transplant</i>. 2014;19:337-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25017487\">[PubMed 25017487]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11281":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / Sarilumab</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sarilumab may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased levels/effects of CYP3A4 substrates (eg, simvastatin) in patients initiated on sarilumab.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 17 patients with rheumatoid arthritis (RA), treatment with sarilumab (200 mg single subcutaneous injection) decreased the simvastatin (40 mg single oral dose given 1 week after sarilumab) AUC and maximum serum concentration (Cmax) 45% and 46%, respectively.<sup>1</sup> The AUC and Cmax of the active metabolite, simvastatin acid, both decreased 36%.<sup>1</sup><br><br>Sarilumab prescribing information states that caution should be used when combining sarilumab and CYP3A4 substrates with narrow therapeutic indexes where a decrease in exposure and effectiveness is undesirable.<sup>2</sup><br><br>Sarilumab binds to and inhibits the proinflammatory cytokine interleukin-6 (IL-6).<sup>2</sup> In vitro, IL-6 decreased CYP3A4 mRNA by greater than 90%.<sup>3</sup> Sarilumab may restore CYP3A4 activity in RA patients and thus increase the metabolism of CYP3A4 substrates. This effect may persist several weeks following discontinuation of therapy due to the long half-life of sarilumab.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee EB, Daskalakis N, Xu C, et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. <i>Clin Pharmacokinet</i>. 2017;56(6):607-615. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27722854\">[PubMed 27722854]</a></p>\n<p>2. Kevzara (sarilumab) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; May 2017. </p>\n<p>3. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6, and 3A4 mRNA levels in human hepatocytes. <i>Drug Metab Dispos</i>. 2007;35(9):1687-1693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17576808\">[PubMed 17576808]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11282":"<p><b>Title</b> MiFEPRIStone / Fosamprenavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Mifepristone dose reduction with this combination is only recommended by the manufacturer of a multiple-dose mifepristone product used for treatment of hyperglycemia in Cushing's syndrome.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosamprenavir may increase the serum concentration of MiFEPRIStone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use mifepristone in combination with fosamprenavir only when necessary. Start mifepristone at a dose of 300 mg/day and titrate to a maximum dose of 600 mg/day when mifepristone is initiated for treatment of hyperglycemia related to Cushing's syndrome in adult patients already being treated with fosamprenavir. When fosamprenavir is initiated in a patient receiving mifepristone for treatment of hyperglycemia related to Cushing's syndrome, adjust the dose of mifepristone as follows: mifepristone 300 mg/day (no dose change), mifepristone 600 mg/day (reduce mifepristone dose to 300 mg/day; titrate to a maximum dose of 600 mg/day, if clinically indicated), mifepristone 900 mg/day (reduce mifepristone dose to 600 mg/day), mifepristone 1200 mg/day (reduce mifepristone dose to 600 mg/day). Monitor for increased mifepristone toxicity regardless of dose or indication.</p> \n<p><b>Discussion</b> In a clinical study summarized in the mifepristone prescribing information, coadministration of mifepristone (600 mg daily for 17 days) and the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily on days 13 to 17) increased the mifepristone AUC and maximum serum concentration by 38% and 28%, respectively.<sup>1</sup> In the same study, the AUC of one active metabolite increased 67%, while the AUCs of two other active metabolites were essentially unchanged.<sup>1</sup> Prescribing information for one mifepristone product, indicated for treatment of hyperglycemia in Cushing's syndrome, recommends limiting the mifepristone dose to a maximum of 600 mg/day in patients receiving concomitant strong CYP3A4 inhibitors.<sup>1</sup> The manufacturer of a single-dose mifepristone product indicated for pregnancy termination mentions the possibility of an interaction with strong CYP3A4 inhibitors, based on the primary role of CYP3A4 in mifepristone metabolism, but does not recommend mifepristone dose reduction.<sup>2</sup><br><br>Although typically considered moderate CYP3A4 inhibitors, the mifepristone prescribing information also lists fosamprenavir and conivaptan as agents that should be used with mifepristone only when necessary.<sup>1</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for mifepristone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Inc; May 2017.</p>\n<p>2. Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories, LLC; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11283":"<p><b>Title</b> MiFEPRIStone / Conivaptan</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Mifepristone dose reduction with this combination is only recommended by the manufacturer of a multiple-dose mifepristone product used for treatment of hyperglycemia in Cushing's syndrome.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of MiFEPRIStone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use mifepristone in combination with conivaptan only when necessary. Start mifepristone at a dose of 300 mg/day and titrate to a maximum dose of 600 mg/day when mifepristone is initiated for treatment of hyperglycemia related to Cushing's syndrome in adult patients already being treated with conivaptan. When conivaptan is initiated in a patient receiving mifepristone for treatment of hyperglycemia related to Cushing's syndrome, adjust the dose of mifepristone as follows: mifepristone 300 mg/day (no dose change), mifepristone 600 mg/day (reduce mifepristone dose to 300 mg/day; titrate to a maximum dose of 600 mg/day, if clinically indicated), mifepristone 900 mg/day (reduce mifepristone dose to 600 mg/day), mifepristone 1200 mg/day (reduce mifepristone dose to 600 mg/day). Monitor for increased mifepristone toxicity regardless of dose or indication.</p> \n<p><b>Discussion</b> In a clinical study summarized in the mifepristone prescribing information, coadministration of mifepristone (600 mg daily for 17 days) and the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily on days 13 to 17) increased the mifepristone AUC and maximum serum concentration by 38% and 28%, respectively.<sup>1</sup> In the same study, the AUC of one active metabolite increased 67%, while the AUCs of two other active metabolites were essentially unchanged.<sup>1</sup> Prescribing information for one mifepristone product, indicated for treatment of hyperglycemia in Cushing's syndrome, recommends limiting the mifepristone dose to a maximum of 600 mg/day in patients receiving concomitant strong CYP3A4 inhibitors.<sup>1</sup> The manufacturer of a single-dose mifepristone product indicated for pregnancy termination mentions the possibility of an interaction with strong CYP3A4 inhibitors, based on the primary role of CYP3A4 in mifepristone metabolism, but does not recommend mifepristone dose reduction.<sup>2</sup><br><br>Although typically considered moderate CYP3A4 inhibitors, the mifepristone prescribing information also lists conivaptan and fosamprenavir as agents that should be used with mifepristone only when necessary.<sup>1</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for mifepristone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Inc; May 2017.</p>\n<p>2. Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories, LLC; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}